Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Orion Pharma.

    Client Virtual Booth

    ORION PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Orion Pharma
    Bangladesh Flag
    Country
    Country
    Bangladesh
    Address
    Address
    Orion House, 153-154 Tejgaon Industrial Area Dhaka-1208
    Telephone
    Telephone
    +88 02 8870133
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.orionpharmabd.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Orion Enters Into Exclusive Agreement with Jemincare for Novel Non-Opioid Drug Candidate for The Treatment of Pain

    Details:

    According to the agreement, Orion has the right to develop and commercialise the JMKX000623, NaV 1.8 blocker asset in its territory. Orion will be fully responsible for its own development and commercialisation costs.


    Lead Product(s): JMKX000623

    Therapeutic Area: Neurology Product Name: JMKX000623

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Recipient: Jemincare

    Deal Size: Undisclosed Upfront Cash: $15.8 million

    Deal Type: Agreement May 06, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation

    Details:

    Under the agreement, Alligator Bioscience will employ its proprietary phage display libraries and RUBY™ bispecific platform to develop immuno-oncology product candidates based on design criteria identified by Orion.


    Lead Product(s): Bispecific Antibody

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Large molecule

    Recipient: Alligator Bioscience

    Deal Size: $552.8 million Upfront Cash: Undisclosed

    Deal Type: Collaboration August 18, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search